Lindsey Burggraaff is a Ph.D. student at the Division of Medicinal Chemistry and works on a computational approach to predict target selectivity of ligands.
Before I started as a PhD student at Leiden University I studied Pharmaceutical Sciences at VU Amsterdam. In 2013 I obtained my Bachelor’s degree and decided to do the follow-up research master “Drug Discovery & Safety”. During this master I completed the specialization courses of both “Drug Discovery & Target Finding” and “Computational Medicinal Chemistry & Toxicology”. Although I always had a certain interest in computational chemistry, my interest in computational medicinal chemistry was strengthened by my challenging major internship in the medicinal chemistry group at the VU where I focused on obtaining selectivity in phosphodiesterases. I graduated and received my Master’s degree in “Drug Discovery & Safety” with a specialization in “Computational Medicinal Chemistry & Toxicology” in 2015.
Currently I am doing my PhD research in the medicinal chemistry group of Prof. IJzerman. Under the lead of Dr. van Westen I will work on a computational approach to predict target selectivity of ligands. The main focus will be on proteochemometric (PCM) modeling of G protein-coupled receptors (GPCRs). With this technique protein information and ligand data are combined and cross-linked, resulting in predictive models. Subsequently, these models can be applied to predict selectivity of ligands in mutated carcinogenic receptors. Ultimately, these models may guide personalized medicine based on genotypic information.